Jalbă C S, Jalbă B A, Nicula Corina, Zlatian O, Ioana M, Bârcă Amelia, Cimpoeru Alina, Cruce M
Prof. Dr. Dimitrie Gerota Emergency Hospital, Bucharest, Romania.
Rom J Morphol Embryol. 2011;52(3):775-81.
To study the expression status and clinical relevance of vascular endothelial growth factor-A (VEGF-A) in colorectal cancer (CRC) tissues.
VEGF-A expression was investigated by immunohistochemistry in 89 cases with CRC. Some demographic and histopathological variables were compared with VEGF-A expression to determine the prognostic significance in CRC.
VEGF-A (-) was found in 24 cases; (+), (++) and (+++) stainings were detected in 24, 35 and six cases, respectively. VEGF-A (-) was found in 20 of 58 cases with left colon cancer, while only four of 31 cases with right colon cancer were VEGF-A (-) (p=0.024). There was a trend for lower tumor grade and lesser serosal invasion in cases with VEGF-A (-) samples (p=0.07 and p=0.079, respectively). Although the correlation was not statistically significant, there was a trend for lower death rate in cases with VEGF-A (-) tumor (p=0.087). The longest survival was found in cases with VEGF-A (-) tumor and the shortest survival was found in cases with VEGF-A (+++) tumor. Median survival for patients with VEGF-A (-), (+), (++) and (+++) tumors was 59, 47, 35 and 11 months, respectively (p=0.02). The Cox proportional hazards model identified stage IV disease and VEGF-A (+++) tumor as having the most important influences upon overall survival (odds ratio: 5.1, 95% confidence interval: 2.0-13.0 and odds ratio: 3.6, 95% confidence interval: 1.0-12.7, respectively), followed by serosal invasion (odds ratio: 2.4, 95% confidence interval: 1.0-5.9).
This study shows that VEGF-A is a poor prognostic factor in cases with CRC, but the relatively small size of the study group precluded the correlation with the entire known prognostic indicator.
研究血管内皮生长因子-A（VEGF-A）在结直肠癌（CRC）组织中的表达状况及其临床相关性。
采用免疫组织化学方法检测89例CRC患者的VEGF-A表达情况。将一些人口统计学和组织病理学变量与VEGF-A表达进行比较，以确定其在CRC中的预后意义。
24例患者VEGF-A（-）；24例、35例和6例分别检测到（+）、（++）和（+++）染色。58例左结肠癌患者中有20例VEGF-A（-），而31例右结肠癌患者中只有4例VEGF-A（-）（p = 0.024）。VEGF-A（-）样本的患者肿瘤分级较低且浆膜侵犯较少（分别为p = 0.07和p = 0.079）。虽然相关性无统计学意义，但VEGF-A（-）肿瘤患者的死亡率有降低趋势（p = 0.087）。VEGF-A（-）肿瘤患者的生存期最长，VEGF-A（+++）肿瘤患者的生存期最短。VEGF-A（-）、（+）、（++）和（+++）肿瘤患者的中位生存期分别为59个月、47个月、35个月和11个月（p = 0.02）。Cox比例风险模型确定IV期疾病和VEGF-A（+++）肿瘤对总生存期影响最为重要（风险比分别为：5.1，95%置信区间：2.0 - 13.0；风险比为：3.6，95%置信区间：1.0 - 12.7），其次是浆膜侵犯（风险比：2.4，95%置信区间：1.0 - 5.9）。
本研究表明，VEGF-A是CRC患者的不良预后因素，但研究组规模相对较小，妨碍了其与所有已知预后指标的相关性分析。
